Comparability of European League Against Rheumatology-Recommended Pharmacological Treatments of Oral Ulcers Associated with Behçet’s Disease: A Systematic Literature Review of Randomized Controlled Trials

References

• Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–818.29625968
   PubMed Web of Science ®Google Scholar
• Cansu D, Kaşifoğlu T, Korkmaz C. Is there any relationship between season/weather and oral ulcer in Behçet’s disease? Eur J Rheumatol. 2014;1(3):89–91. doi:10.5152/eurjrheumatol.2014.03127708885
   PubMedGoogle Scholar
• Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B. Review of the chronology of clinical manifestations in 60 patients with Behçet’s disease. Dermatology. 2003;207(4):354–356. doi:10.1159/00007411314657625
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shahram F, Chams-Davatchi C, et al. Behçet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13(4):367–373. doi:10.1111/j.1756-185X.2010.01549.x21199472
   PubMed Web of Science ®Google Scholar
• Gur A, Sarac AJ, Burkan YK, Nas K, Cevik R. Arthropathy, quality of life, depression, and anxiety in Behçet’s disease: relationship between arthritis and these factors. Clin Rheumatol. 2006;25(4):524–531. doi:10.1007/s10067-005-0100-616639519
   PubMed Web of Science ®Google Scholar
• Krause L, Köhler A-K, Altenburg A, et al. Ocular involvement in Adamantiades-Behçet’s disease in Berlin, Germany. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):661–666. doi:10.1007/s00417-008-0983-418982344
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine. 2003;82(1):60–76. doi:10.1097/00005792-200301000-0000612544711
   PubMed Web of Science ®Google Scholar
• Sola-Morales O, Mehta S, Ronnebaum S, et al. A systematic literature review of healthcare burden in patients with Behçet’s disease. Poster presented at: the European Congress of Rheumatology EULAR 2019; 12–156 2019; Madrid, Spain; 2019.
   Google Scholar
• International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet (London, England). 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Akkoc N. Update on the epidemiology, risk factors and disease outcomes of Behçet’s disease. Best Pract Res Clin Rheumatol. 2018;32(2):261–270. doi:10.1016/j.berh.2018.08.01030527431
   PubMed Web of Science ®Google Scholar
• Naito M, Suzukamo Y, Wakai K, et al. One-year period prevalence of oral aphthous ulcers and oral health-related quality of life in patients with Behçet’s disease. Genet Res Int. 2014;2014:930348.24734187
   PubMedGoogle Scholar
• Ambrose NL, Haskard DO. Differential diagnosis and management of Behçet syndrome. Nat Rev Rheumatol. 2013;9(2):79–89.23007742
   PubMed Web of Science ®Google Scholar
• Greco A, De Virgilio A, Ralli M, et al. Behçet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567–575. doi:10.1016/j.autrev.2017.12.00629631062
   PubMed Web of Science ®Google Scholar
• Mumcu G, Ergun T, Inanc N, et al. Oral health is impaired in Behçet’s disease and is associated with disease severity. Rheumatology. 2004;43(8):1028–1033. doi:10.1093/rheumatology/keh23615161982
   PubMed Web of Science ®Google Scholar
• Mumcu G, Inanc N, Ergun T, et al. Oral health related quality of life is affected by disease activity in Behçet’s disease. Oral Dis. 2006;12(2):145–151. doi:10.1111/j.1601-0825.2005.01173.x16476035
   PubMed Web of Science ®Google Scholar
• Senusi A, Higgins S, Fortune F. The influence of oral health and psycho-social well-being on clinical outcomes in Behçet’s disease. Rheumatol Intl. 2018;38(10):1873–1883. doi:10.1007/s00296-018-4117-y
   Web of Science ®Google Scholar
• Canpolat Ö, Yurtsever S. The quality of life in patients with Behçet’s disease. Asian Nurs Res. 2011;5(4):229–235. doi:10.1016/j.anr.2011.12.003
   Web of Science ®Google Scholar
• Güler T, Çifci Aslan N, Garip Y, Dörtbaş F, Aslihan A. Disease activity in Turkish patients with Behçet’s disease: association with fatigue, psychological status and quality of life. Turkiye Klinikleri J Med Sci. 2017;37(3):130–135. doi:10.5336/medsci.2017-56200
   Google Scholar
• Melikoğlu M, Melikoglu MA. What affects the quality of life in patients with Behçet’s disease? Acta Reumatol Port. 2014;39(1):46–53.24811461
   PubMed Web of Science ®Google Scholar
• Bernabé E, Marcenes W, Mather J, Phillips C, Fortune F. Impact of Behçet’s syndrome on health-related quality of life: influence of the type and number of symptoms. Rheumatology. 2010;49(11):2165–2171. doi:10.1093/rheumatology/keq25120675710
   PubMed Web of Science ®Google Scholar
• Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome. Semin Arthritis Rheum. 2019;48(4):752–762. doi:10.1016/j.semarthrit.2018.05.00829954598
   PubMed Web of Science ®Google Scholar
• Otezla® tablets [updated]; 2019 Available from: https://otezla-japan.jp/dr/. Accessed 1111, 2020.
   Google Scholar
• Otezla® (apremilast) [package insert]. Summit, NJ: Amgen Inc.; June 2020.
   Google Scholar
• Otezla (apremilast) [SmPC]. Breda, Netherlands: Amgen Europe B.V.; 2020.
   Google Scholar
• Nava F, Ghilotti F, Maggi L, et al. Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for neuro-Behçet’s syndrome. Cochrane Database Syst Rev. 2014;(12):CD010729.25521793
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi:10.1136/bmj.j141528404617
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–428.21669366
   PubMed Web of Science ®Google Scholar
• Facey KM. As health technology assessment evolves so must its approach to patient involvement. J Comp Eff Res. 2019;8(8):549–554. doi:10.2217/cer-2019-003931116026
   PubMed Web of Science ®Google Scholar
• Es-Skali IJ, Spoors J. Analysis of indirect treatment comparisons in national health technology assessments and requirements for industry submissions. J Comp Eff Res. 2018;7(4):397–409. doi:10.2217/cer-2017-009229589475
   PubMed Web of Science ®Google Scholar
• Laws A, Kendall R, Hawkins N. A comparison of national guidelines for network meta-analysis. Value Health. 2014;17(5):642–654. doi:10.1016/j.jval.2014.06.00125128059
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011 Available from: www.handbook.cochrane.org. Accessed 1111, 2020.
   Google Scholar
• Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93. doi:10.1186/1741-7015-12-9324898705
   PubMed Web of Science ®Google Scholar
• Ergun T, Gurbuz O, Yurdakul S, Hamuryudan V, Bekiroglu N, Yazici H. Topical cyclosporine-A for treatment of oral ulcers of Behçet’s syndrome. Int J Dermatol. 1997;36(9):720. doi:10.1111/j.1365-4362.1997.tb03133.x9352422
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome - a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–1518. doi:10.1056/NEJMoa140868425875256
   PubMed Web of Science ®Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med. 2019;381(20):1918–1928. doi:10.1056/NEJMoa181659431722152
   PubMed Web of Science ®Google Scholar
• Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65(3):399–402.6778795
   PubMed Web of Science ®Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542–549. doi:10.3109/s10165-009-0200-219597921
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet (London, England). 1989;333(8647):1093–1096. doi:10.1016/S0140-6736(89)92381-7
   Google Scholar
• Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet’s disease. Dermatology. 1996;192(2):125–128. doi:10.1159/0002463368829493
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44(11):2686–2692. doi:10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H11710724
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–471. doi:10.1001/archderm.138.4.46711939808
   PubMed Web of Science ®Google Scholar
• Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee Sarvestani S. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behçet’s syndrome. Iran Red Crescent Med J. 2012;14(2):75–78.22737559
   PubMed Web of Science ®Google Scholar
• Kiliç H, Zeytin HE, Korkmaz C, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet’s syndrome. Rheumatology. 2009;48(11):1388–1391. doi:10.1093/rheumatology/kep23719717547
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet’s syndrome: a randomized, double blind trial. Br J Rheumatol. 1991;30(5):395–396. doi:10.1093/rheumatology/30.5.395-a
   PubMedGoogle Scholar
• Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443–450. doi:10.7326/0003-4819-128-6-199803150-000049499327
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98–105.15630733
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322(5):281–285. doi:10.1056/NEJM1990020132205012404204
   PubMed Web of Science ®Google Scholar
• Rath A, Salamon V, Peixoto S, et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials. 2017;18(1):556. doi:10.1186/s13063-017-2287-729166947
   PubMed Web of Science ®Google Scholar
• Hatemi G, Meara A, Ozguler Y, et al. Developing a core set of outcome measures for Behçet disease: report from OMERACT 2016. J Rheumatol. 2017;44(11):1750–1753. doi:10.3899/jrheum.16135228365574
   PubMed Web of Science ®Google Scholar
• Hatemi G, Meara A, Ozguler Y, et al. THU0303 The OMERACT core domain set for clinical trials in Behçet’s syndrome. Ann Rheum Dis. 2019;78(Suppl 2):431.30282666
   PubMed Web of Science ®Google Scholar
• Friede T, Röver C, Wandel S, Neuenschwander B. Meta-analysis of few small studies in orphan diseases. Res Synth Methods. 2017;8(1):79–91. doi:10.1002/jrsm.121727362487
   PubMed Web of Science ®Google Scholar
• Khabbazi A, Karkon Shayan F, Ghojazadeh M, et al. Adherence to treatment in patients with Behçet’s disease. Int J Rheum Dis. 2018;21(12):2158–2166. doi:10.1111/1756-185X.1310928627044
   PubMed Web of Science ®Google Scholar